0.549

12.73% 0.0616

Atyr Pharma Inc (ATYR)

Overview News Price History Discussions Forecast

Atyr Pharma Inc stock is traded at $0.549, with a volume of 4.49M. It is up +12.73% in the last 24 hours and down -28.18% over the past month. aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

Previous Close:

$0.4874

Open:

$0.5354

24h Volume:

4.49M

Relative Volume:

2.23

Market Cap:

$53.83M

Revenue:

$190.00K

Net Income/Loss:

$-74.12M

P/E Ratio:

-0.6895

EPS:

-0.7962

Net Cash Flow:

$-62.06M

1W Performance:

+12.13%

1M Performance:

-28.18%

6M Performance:

-29.60%

1Y Performance:

-87.09%

1-Day Range:

$0.52

$0.5659

1-Week Range:

$0.464

$0.5659

52-Week Range:

$0.395

$7.2904

Atyr Pharma Inc Stock (ATYR) Company Profile

Name

Atyr Pharma Inc

Sector

Healthcare (1105)

Industry

Biotechnology (624)

Phone

(858) 731-8389

Address

10240 SORRENTO VALLEY ROAD, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-05-20

Latest SEC Filings

ATYR's Discussions on Twitter

Compare ATYR vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATYR Atyr Pharma Inc	0.549	47.79M	190.00K	-74.12M	-62.06M	-0.7962
VRTX Vertex Pharmaceuticals Inc	447.40	113.70B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	613.22	65.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	833.39	52.14B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	300.31	40.73B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.17	32.87B	742.00K	-1.37B	-1.07B	-7.0731

Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-16-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-15-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-15-25	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-15-25	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-15-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-18-25	Initiated	Leerink Partners	Outperform
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight
Oct-04-24	Initiated	Wells Fargo	Overweight
Sep-05-24	Initiated	Jefferies	Buy
Jul-05-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-12-21	Initiated	RBC Capital Mkts	Outperform
Sep-21-21	Initiated	Piper Sandler	Overweight
May-10-21	Initiated	Laidlaw	Buy
Aug-17-20	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-04-20	Initiated	ROTH Capital	Buy
Mar-02-20	Initiated	Oppenheimer	Outperform
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-07-17	Initiated	Piper Jaffray	Overweight
Dec-13-16	Downgrade	JP Morgan	Overweight → Neutral
Dec-16-15	Initiated	Citigroup	Neutral
Jun-01-15	Initiated	Citigroup	Buy
Jun-01-15	Initiated	JP Morgan	Overweight

View All

Atyr Pharma Inc Stock (ATYR) Latest News

May 28, 2026

aTyr Pharma plans new phase 3 trial for pulmonary sarcoidosis drug - Investing.com Nigeria

May 27, 2026

May 24, 2026

Why Is aTyr Stock Falling Today? - MSN

May 24, 2026

May 21, 2026

ATyr Pharma revamps efzofitimod path with new phase III sarcoidosis trial - MSN

May 21, 2026

May 20, 2026

aTyr Pharma stock (US53227K1025): clinical pipeline update keeps biotech in focus - AD HOC NEWS

May 20, 2026

Freedom Capital Markets Initiates ATyr Pharma(ATYR.US) With Buy Rating, Announces Target Price $3.5 - Moomoo

May 20, 2026

ATYR Upgraded by Freedom Broker -- Price Target Raised to $3.50 - GuruFocus

May 20, 2026

ATyr Pharma Raised to Buy From Hold by Freedom Broker - Moomoo

May 20, 2026

ATyr Pharma Price Target Raised to $3.50/Share From $1.00 by Freedom Broker - Moomoo

May 20, 2026

aTyr Pharma upgraded to Buy from Hold at Freedom Broker - TipRanks

May 20, 2026

Freedom Broker upgrades ATYR Pharma (ATYR) - MSN

May 20, 2026

May 19, 2026

Atyr plans new global clinical trial of efzofitimod in pulmonary sarcoidosis - Sarcoidosis News

May 19, 2026

aTyr Pharma(ATYR) Stock Options Chain | Quotes & News - Moomoo

May 19, 2026

aTyr Pharma stock (US0021202025): fresh quarterly loss keeps biotech in focus - AD HOC NEWS

May 19, 2026

May 18, 2026

Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1 - Moomoo

May 18, 2026

Number of shareholders of aTyr Pharma, Inc. – NASDAQ:ATYR - TradingView

May 18, 2026

May 17, 2026

Number of shareholders of aTyr Pharma, Inc. – LS:A2PM86 - TradingView

May 17, 2026

aTyr Pharma Inc stock (US53227K1025): biotech under pressure as short interest jumps and earnings su - AD HOC NEWS

May 17, 2026

May 15, 2026

JonesTrading Maintains ATyr Pharma(ATYR.US) With Hold Rating - Moomoo

May 15, 2026

[10-Q] aTYR PHARMA INC Quarterly Earnings Report - Stock Titan

May 15, 2026

aTyr: Advancing Efzofitimod for Pulmonary Sarcoidosis - GuruFocus

May 15, 2026

aTyr Pharma Inc options imply 30.5% move in share price post-earnings - TipRanks

May 15, 2026

aTyr Pharma Reports Q1 2026 Results, Advances Efzofitimod Phase 3 for Pulmonary Sarcoidosis After FDA Meeting - Minichart

May 15, 2026

ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 15, 2026

aTyr Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 15, 2026

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update - The Manila Times

May 15, 2026

Atyr Pharma: Q1 Earnings Snapshot - marketscreener.com

May 15, 2026

aTyr Pharma (NASDAQ: ATYR) details Q1 2026 loss and Phase 3 plan - Stock Titan

May 15, 2026

May 14, 2026